Hiperson-D

Quick links to important sections

Hiperson-D

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hiperson-D

Quick Facts

Property Description
Active ingredient Enalapril (ACE Inhibitor) and Hydrochlorothiazide (Thiazide Diuretic)
Form Tablet (Oral Dosage Form)
Pharmacological class ACE Inhibitor with a Thiazide Diuretic (Antihypertensive Combination)
Common use Management of High Blood Pressure (Hypertension)
Origin Synthetic

What Type of Medicine Is Hiperson-D?

Hiperson-D is a prescription-only antihypertensive agent formulated as a synthetic fixed-dose combination (FDC) medicine, delivered as an orally-active tablet. The principle of combining active ingredients into an FDC is clinically recognized for supporting patient adherence to treatment regimens required for chronic conditions such as high blood pressure. Containing Enalapril and Hydrochlorothiazide together, Hiperson-D is an example of a widely used dual-agent formulation in the management of hypertension, also available under other commercial names.

Active Ingredients and Pharmacological Class

Both Enalapril and Hydrochlorothiazide are the two core active ingredients in the Hiperson-D tablet. This specific formulation is classified as an ACE Inhibitor with a Thiazide Diuretic, combining agents from two complementary pharmacological classes. Enalapril is a prodrug belonging to the Angiotensin-Converting Enzyme (ACE) Inhibitor class, while Hydrochlorothiazide is a Thiazide Diuretic, commonly referred to as a "water pill." The strategy of combining these classes allows for targeting two regulatory systems in the body.

The General Purpose of This Dual-Action Therapy

The general purpose of Hiperson-D is the comprehensive, sustained control of hypertension (High Blood Pressure) using a powerful dual-action strategy. The medicine's design leverages the complementary effects of an agent that relaxes blood vessels and one that reduces fluid volume. This comprehensive approach is employed to effectively lower the pressure exerted on the arteries, which reduces strain on the heart and circulatory system over time, thereby constituting its primary therapeutic use.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Hiperson-D?

Official Safety Profile of Hiperson-D

The official safety profile for Hiperson-D (Enalapril/Hydrochlorothiazide) is defined by government regulatory documents, classifying possible effects by frequency and the body system affected.

Frequency and System-Organ Classes

Adverse reactions are formally classified. Common effects, reported in at least 1% of patients, include dizziness, headache, fatigue, and a persistent dry cough, which is characteristic of the ACE inhibitor component. Uncommon reactions involve the gastrointestinal system (nausea, diarrhea), skin (rash), and vascular system (hypotension, syncope). Regulatory documentation groups effects into specific System-Organ Classes, such as Nervous System Disorders, Vascular Disorders, and Metabolism and Nutrition Disorders.

Serious Adverse Reactions and Constraints

The regulatory profile highlights specific, serious adverse reactions. The most critical risk documented is angioedema, a rapid swelling of the face, throat, or tongue, which is classified as potentially life-threatening. Other serious documented risks include acute renal failure and severe electrolyte imbalances (low or high potassium levels), and acute angle-closure glaucoma. Safety information notes that symptomatic hypotension is more likely to occur early in the course of therapy.

Population-Specific Restrictions

Use is restricted by several safety considerations: The medication is contraindicated during the second and third trimesters of pregnancy due to documented risk to the fetus, and it is also contraindicated in patients with anuria (absence of urine production) or a history of angioedema related to prior ACE inhibitor therapy. Safety and efficacy have not been established in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Hiperson-D is officially documented as primarily manifesting through the extension of its pharmacological effects, leading to Profound Hypotension and Volume Depletion. Clinical signs associated with overdosage may include Syncope (fainting), Lightheadedness, and a risk of severe Electrolyte Imbalances, such as Hypokalemia, due to the diuretic component. The primary toxicological effects involve the Cardiovascular, Renal, and Metabolic Systems.

Severe Outcomes and Mandatory Actions

The regulatory profile notes that excessive blood pressure lowering can lead to Acute Renal Failure, Progressive Azotemia, or, in high-risk patients with existing disease, acute Myocardial Infarction or Stroke. The onset of Angioedema causing Laryngeal Edema is classified as a life-threatening complication that requires immediate action.

When to Seek Immediate Medical Help

Seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the affected individual has collapsed, has trouble breathing, or cannot be awakened. The medicine must be promptly discontinued upon suspicion of an overdose or a severe event.

Official Management and Monitoring

Management is symptomatic and supportive. The official guidance requires the patient be placed in the supine position and treated with an Intravenous Infusion of Normal Saline to manage hypotension and volume depletion. There is no specific antidote documented. Close monitoring of vital signs, serum electrolytes, and renal function (BUN/Creatinine) is required during recovery.

Therapeutic Uses of Hiperson-D

What Hiperson-D Treats: Main Uses and Benefits

Hiperson-D is commonly used for managing high blood pressure (hypertension) in adults. It is generally applied in conditions presenting with symptoms related to sustained systemic imbalance and heightened physiological activity that creates noticeable physiological strain.

Dual-Agent Control for Persistent Elevation

This medication plays a role in managing symptoms linked to organ-specific functional stress, which may become more disruptive during phases when symptoms become more noticeable. Clinically, it is applied in scenarios where additional management of discomfort is required, utilizing a dual-agent approach when symptom management with a single agent requires additional support. The combination generally helps to ease symptoms related to systemic imbalance and supports functional stability.

Long-Term Support for Functional Stability

The long-term focus is to provide support that helps ease the overall symptom load associated with chronic hypertension. This approach supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened physiological activity.


Quick Fact: Support for Systemic Imbalance
Primary Indication Essential Hypertension (High Blood Pressure) in adults.
Use Scenario Step-Up Therapy; Maintenance Therapy.
Symptom Domain Symptoms related to systemic imbalance and organ-specific functional stress.
Patient Benefit Assists with maintaining functional stability and contributes to easing the overall symptom load.

Regulatory References

  1. Enalapril and Hydrochlorothiazide: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Hiperson-D?

The population eligibility for using Hiperson-D (Enalapril/Hydrochlorothiazide) is strictly defined by regulatory documents, distinguishing between approved groups, restricted use, and absolute contraindications.

Contraindicated Populations

Use of Hiperson-D is contraindicated in several groups due to severe risks:

  • Pregnancy: Contraindicated during the second and third trimesters. Discontinuation is mandatory immediately upon pregnancy detection.
  • Angioedema: Patients with a history of angioedema related to any prior ACE Inhibitor treatment, or hereditary angioedema.
  • Anuria (inability to pass urine) or known hypersensitivity to the drug components or to sulfonamide-derived drugs.
  • Drug Interactions: Patients concurrently taking Aliskiren with diabetes or moderate-to-severe renal impairment, or patients taking Sacubitril/Valsartan within a 36-hour period.

Age and Condition Restrictions

Category Regulatory Status
Age (Pediatric) Not recommended; safety and effectiveness have not been established in patients under 18 years of age.
Age (Geriatric) Use requires caution due to a higher likelihood of age-related functional impairment.
Renal Impairment Contraindicated in severe renal impairment ( Creatinine Clearance le 30 mL/min).
Hepatic Impairment Use requires caution in impaired hepatic function due to the risk of hepatic coma.
Lactation Not recommended; both components are excreted in human milk.

Use is approved for adults with essential hypertension for whom combination therapy is deemed appropriate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific interaction patterns for Hiperson-D (Enalapril/Hydrochlorothiazide), focusing on pharmacokinetic and pharmacodynamic risks.

Formally Contraindicated Combinations

Co-administration with Sacubitril/Valsartan is strictly contraindicated due to the risk of angioedema; a mandatory 36-hour separation period is required when switching between the two. The use of Aliskiren is also contraindicated in patients with diabetes mellitus or those with moderate to severe renal impairment.

Pharmacodynamic and Electrolyte Risks

Interaction with Potassium Supplements and Potassium-Sparing Diuretics is documented due to the increased risk of hyperkalemia (high potassium levels). Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect and increase the risk of renal impairment. Lithium clearance is reduced by Hiperson-D, which raises the risk of lithium toxicity.

Absorption and Alcohol Effects

Agents such as Cholestyramine and Colestipol interfere with the absorption of the Hydrochlorothiazide component, reducing its systemic exposure. Additionally, Alcohol may cause additive effects in lowering blood pressure, including the potentiation of orthostatic hypotension.

Mechanism of Action

Hiperson-D functions as a highly selective non-peptide Angiotensin II Type 1 receptor (AT1 R) antagonist. The drug selectively localizes to vascular smooth muscle and renal tissues. At the molecular level, Hiperson-D competitively binds to and blocks the AT1 R, preventing the binding of the endogenous agonist, Angiotensin II.

This AT1 R blockade inhibits the Gq protein-coupled signaling pathway. Intracellularly, this inhibition suppresses the downstream activation of Phospholipase C (PLC) and the subsequent increase in inositol trisphosphate (IP3 ) and diacylglycerol (DAG). The resultant effect is a significant reduction in the release of intracellular Ca^2+ stores from the sarcoplasmic reticulum and the attenuation of protein kinase C (PKC) activity. The ultimate cellular consequence in vascular smooth muscle cells is a decrease in vasoconstriction and smooth muscle proliferation. System-level physiological modulation involves AT1 R antagonism in the kidney, which increases sodium and water excretion, and an overall reduction in peripheral vascular resistance due to arteriole and venule dilation.

Dosage and Administration Information

How to Use Hiperson-D: Official Administration Guidelines

Hiperson-D is an oral medication, typically taken as a tablet once per day. Its administration is independent of mealtimes, meaning it can be taken either with or without food. As a fixed-dose combination (FDC), this medicine is generally not intended for initial therapy but is reserved for the long-term maintenance management of high blood pressure in adult patients. It is appropriately used to replace the individual components (Enalapril and Hydrochlorothiazide) after a patient's dose has been separately established and stabilized.


Labeled Dosing and Scheduling

The standard adult dosage is one tablet per day. Since the medication is prescribed for chronic conditions, treatment is typically continued for as long as control is required and the medicine is tolerated. If a dose is missed, it is typically taken as soon as remembered; however, if the time is near the next scheduled dose, the missed dose is skipped entirely. The dose must never be doubled to compensate for a missed one.


Population and Procedural Constraints

The use of Hiperson-D is not recommended in patients with severe renal impairment (Creatinine Clearance less than 30 mL/min) due to the presence of the diuretic component. Safety and effectiveness have not been established for use in the pediatric population (patients under 18 years of age). If a change in therapy or dosage adjustment becomes necessary during maintenance, the dose is adjusted using the individual components rather than altering the fixed-dose combination itself.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hiperson-D

Evidence Base for Essential High Blood Pressure

Hiperson-D was studied for Essential Hypertension (high blood pressure) in adults. The research primarily consists of Randomized Controlled Trials (RCTs), sometimes summarized in Systematic Reviews. Hiperson-D is most relevant in studies examining temporary physiological imbalance in people whose blood pressure was evaluated when not controlled by using only Enalapril (one of the ingredients). These trials studied for changes measured during the study period, reporting how symptoms evolved over short- to intermediate-term follow-up periods.


How the Combination Was Studied Against Single-Ingredient Therapy

The specific studies for Hiperson-D compared the combination tablet directly against the use of a single active ingredient, usually Enalapril, in double-blind designs. Studies monitored the rate of patients reaching a predefined blood pressure goal. Research described patterns observed in measured changes in blood pressure when the combination was evaluated against the administration of Enalapril alone. Research also described differences in responses across various racial/ethnic subgroups, with certain studies reporting observed patterns related to the diuretic component in some Black hypertensive patients.


Long-Term Data and Maintenance of Effect

The key comparative RCTs were typically short- to intermediate-term. Because of these limited follow-up durations, long-term effects are not fully established based solely on the fixed-dose combination trials. The research for the combination's long-term outcomes, such as its impact on major cardiovascular events, is often derived from much larger, long-term studies conducted using the individual components or similar combination classes.


Research in Specific Patient Groups and Gaps in Uncertainty

The primary study populations research examined adults (18 years and older) with Essential Hypertension. Research explored how symptoms change over time in older adults. However, data for certain groups remain insufficient, especially for patients with complex coexisting medical conditions. The results apply only to the populations studied under the specific research conditions. The evidence base was not studied for use as the initial treatment for hypertension, and comparative evidence is lacking for that scenario. Research does not determine whether an individual will respond similarly; the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. PRODUCT MONOGRAPH Pr ENALAPRIL/HCTZ (enalapril and hydrochlorothiazide tablets) - Health Canada
  2. Enalapril and Hydrochlorothiazide: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Hiperson-D (FAQ)


Q: How fast does Hiperson-D usually start working?

A: Official information indicates that the diuretic (water pill) component of Hiperson-D typically exhibits its initial effect within about two hours. While this component acts relatively quickly, the full therapeutic benefit of the combination to manage blood pressure generally develops gradually over a period of consistent use.


Q: Is it normal to feel a bit dizzy when first starting Hiperson-D?

A: Dizziness is noted in regulatory documents as a common side effect of this medication. Official safety documents state that symptomatic low blood pressure (hypotension) that may cause dizziness is often more likely to occur early in the course of therapy.


Q: Can you drive or operate machinery while taking Hiperson-D?

A: Official patient information includes a statement to use caution when driving or operating machinery. This is because possible side effects like dizziness, fatigue, or lightheadedness may affect your ability to perform these tasks safely until you know how the medication affects you.


Q: Can Hiperson-D cause headaches or migraines?

A: Headache is listed in regulatory documents as a common adverse reaction, meaning it is reported in at least 1% of patients in clinical trials. Regulatory documents list headache as a common effect but do not specifically address 'migraines.'


Q: Does Hiperson-D interact with common over-the-counter pain relievers?

A: The official interaction documents list a risk with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers. Regulatory documents indicate this interaction may reduce the antihypertensive effect and increase the risk of changes to renal (kidney) function.


Q: How long do the effects of one dose of Hiperson-D typically last?

A: The medication is designed for once-daily dosing, suggesting the blood pressure maintenance effect is intended to last for approximately 24 hours. The diuretic component, which aids in fluid reduction, has an activity that generally lasts between 6 to 12 hours.


Q: What happens if I forget to take a dose of Hiperson-D?

A: Official regulatory instructions advise taking a missed dose as soon as it is remembered. However, if the time is near the next scheduled dose, the missed dose should be skipped entirely. Official instructions caution against ever doubling the dose to compensate for a missed one.


Q: What happens in the body if Hiperson-D is suddenly stopped?

A: Abruptly stopping antihypertensive therapy may be associated with a return of blood pressure to pre-treatment levels, a concern sometimes referred to as rebound hypertension. Treatment for a chronic condition should not be stopped without guidance from a healthcare professional.


Q: Are there any known severe allergic reactions to Hiperson-D?

A: Yes, regulatory safety documents describe specific serious risks. The most critical risk documented is angioedema (severe swelling of the face, throat, or tongue), which is identified as potentially serious in regulatory documents. Other symptoms of serious hypersensitivity reactions are also noted.


Q: Do other medications reduce the effectiveness of Hiperson-D?

A: Yes, official documentation confirms certain drugs can reduce its effectiveness. For example, NSAIDs may decrease the blood pressure-lowering effect. Agents like Cholestyramine and Colestipol are also documented to interfere with the absorption of the diuretic component.


Q: Can Hiperson-D make you feel tired or drowsy?

A: Official safety information lists fatigue (tiredness) as a common adverse reaction. Drowsiness (sleepiness) is not typically listed as a primary side effect, although fatigue and dizziness are common effects that may be related to changes in alertness.


Q: What age groups are usually prescribed Hiperson-D?

A: Regulatory information indicates the drug is approved for use in adults with essential hypertension. Official safety and effectiveness have not been established for use in the pediatric population (patients under 18 years of age).


Q: Is there a generic version of Hiperson-D available?

A: Hiperson-D contains the active ingredients Enalapril Maleate and Hydrochlorothiazide. This specific dual-agent formulation is available both under the original brand name and as generic versions of the combination.


Q: Does taking Hiperson-D long-term cause any specific health issues?

A: The official safety profile notes that treatment with the diuretic component, particularly long-term use, has been associated with an increased risk of non-melanoma skin cancer. Regulatory information suggests patients should take protective measures against sun exposure to help minimize this potential risk.


Q: Are there specific times of day that are best for taking Hiperson-D?

A: The official dosing is once daily, and it can be taken with or without food. Official information suggests taking it earlier in the day is often preferred to help minimize potential disruption to sleep, as the diuretic component increases the urge to urinate.


Q: Do people gain or lose weight while on Hiperson-D?

A: Weight changes are not listed as common side effects of this medication. However, fluid and electrolyte imbalances are documented risks, and monitoring for fluid changes is documented due to this risk.


Q: Why do doctors prescribe Hiperson-D instead of a similar drug?

A: Fixed-dose combinations (FDCs) are recognized in clinical contexts for potentially simplifying treatment regimens and supporting adherence. Hiperson-D leverages two complementary mechanisms of action: relaxing blood vessels and reducing fluid volume.


Q: Can taking Hiperson-D affect the results of lab tests?

A: Official patient information indicates that this medication may affect the results of certain laboratory tests. Patients are typically advised to inform their healthcare providers and lab workers that they are taking this medication.


Q: Is it true that Hiperson-D has a diuretic effect?

A: Yes. Hiperson-D is a combination product that includes a Thiazide Diuretic, which is commonly called a 'water pill.' This component works in the kidneys to increase the excretion of sodium and water, which is part of the mechanism for lowering blood pressure.


Q: Why do some people take Hiperson-D in the morning and others at night?

A: The medication is taken once daily. The decision on timing is often related to routine and the diuretic component. Taking it earlier in the day is often preferred to help minimize the potential for increased nighttime urination.


Q: Can Hiperson-D be crushed or split if it's a tablet?

A: Hiperson-D is a fixed-dose combination (FDC) tablet. Regulatory guidance generally requires swallowing the tablet whole unless specific instructions from the manufacturer or a pharmacist permit breaking or crushing it.


Q: Is there a risk of becoming dependent on Hiperson-D?

A: Hiperson-D is not classified as an addictive or controlled substance. However, because it is necessary for the management of a chronic condition like high blood pressure, it is important that treatment is not stopped suddenly without medical guidance.


Q: Does Hiperson-D interact with herbal supplements like St. John's Wort?

A: The official regulatory documents do not specifically detail an interaction with St. John's Wort. However, general guidance advises caution against using supplements that contain potassium or those that have their own diuretic effects, as these could interact with the active ingredients.


Q: Can taking Hiperson-D make me more sensitive to cold or heat?

A: Changes in fluid balance due to the diuretic component may affect the body's natural ability to regulate temperature. Patients should be aware that excessive fluid loss (from heat or activity) may lead to signs of dehydration, which can be potentially serious.


Q: What should I do if a side effect from Hiperson-D doesn't go away?

A: Official patient instructions advise that if any side effect is severe or persistent, the healthcare provider should be told immediately. For very serious reactions, such as angioedema, official guidance is to seek immediate medical attention and discontinue the medication.


Q: Is it necessary to have regular blood tests while on Hiperson-D?

A: Due to the documented risks of serious electrolyte imbalances (such as high or low potassium) and potential effects on renal function, official guidelines recommend periodic monitoring via laboratory blood tests.


Q: What is the shelf life of a typical Hiperson-D prescription?

A: The shelf life is determined by the manufacturer and is indicated by the expiration date printed on the product packaging. It is crucial that the medication is not used past this date to ensure its stability and potency.


Q: What are the less common, but possible, side effects of Hiperson-D?

A: The official safety profile groups reactions by frequency. The 'uncommon' side effects are those less frequently reported in clinical studies. These include gastrointestinal issues like nausea and diarrhea, as well as skin rash, low blood pressure (hypotension), and fainting (syncope).


Q: Does Hiperson-D affect hydration levels or fluid balance?

A: Yes, one of the active ingredients is a diuretic that increases water and sodium excretion. Official warnings note that excessive fluid loss from causes like heavy sweating, vomiting, or diarrhea may lead to symptomatic low blood pressure.


Q: Are there any warnings about sunlight exposure while taking Hiperson-D?

A: Yes, official labeling includes a warning that Hiperson-D may make your skin more sensitive to the sun (a condition called photosensitivity). Patients should take protective measures against sun exposure when outdoors.


Q: How long does Hiperson-D stay in your system after stopping it?

A: The active components of Hiperson-D have half-lives (the time it takes for half of the drug to be eliminated) of several hours. Based on the drug's half-life, it takes several days for the medication to be almost entirely eliminated from the body.


Q: Is it common for doctors to adjust the dosage of Hiperson-D over time?

A: Hiperson-D is a fixed-dose combination, and the standard is typically one tablet daily for maintenance. Official guidance suggests that if a change or adjustment to therapy is needed, it should be done using the individual components, rather than altering the fixed-dose combination itself.

How should Hiperson-D be stored and disposed of?

Storage and Disposal Requirements

Hiperson-D (enalapril maleate and hydrochlorothiazide) tablets must be stored strictly according to official regulatory labeling to ensure product integrity and safety.

Storage Conditions

This medicine requires storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The tablets must be protected from moisture and direct light, and storage environments that freeze the product or expose it to excess heat must be avoided. Keep the tablets in their original container with the cap tightly closed.

Safety and Disposal

Official labeling mandates keeping the medicine out of the sight and reach of children at all times. Expired or unused tablets should not be flushed down a toilet or poured down a drain. Disposal should follow local pharmaceutical waste handling instructions, such as using an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hiperson-D found in:

A-Z Index: